

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 723 013 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

24.07.1996 Bulletin 1996/30

(51) Int. Cl.⁶: **C12N 15/12, C07K 14/51,**

C07K 16/22, A61K 38/18,

A61L 27/00, C12N 1/21

(21) Application number: **96200044.4**

(22) Date of filing: **07.04.1989**

(84) Designated Contracting States:

AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: **08.04.1988 US 179406**

15.08.1988 US 232630

23.02.1989 US 315342

(62) Application number of the earlier application in
accordance with Art. 76 EPC: **89904959.7**

(71) Applicant: **STRYKER CORPORATION**
Kalamazoo, Michigan 49003-4085 (US)

(72) Inventors:

• **Opperman, Hermann**
Medway, Massachusetts 02053 (US)

• **Kuberasampath, Thangavel**
Medway, Massachusetts 02053 (US)

• **Rueger, David C.**
West Roxbury, Massachusetts 02132 (US)

(74) Representative: **Price, Vincent Andrew et al**
Graham Watt & Co.

Riverhead
Sevenoaks, Kent TN13 2BN (GB)

Remarks:

This application was filed on 10 - 01 - 1996 as a
divisional application to the application mentioned
under INID code 62.

(54) **Biosynthetic osteogenic proteins and osteogenic devices containing them**

(57) Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth and cartilage in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.

EP 0 723 013 A2

Description

This invention relates to osteogenic devices, to synthetic genes encoding proteins which can induce osteogenesis in mammals and methods for their production using recombinant DNA techniques, to synthetic forms of osteogenic protein, and to bone and cartilage repair procedures using osteogenic device comprising the synthetic proteins.

Mammalian bone tissue is known to contain one or more proteinaceous materials, presumably active during growth and natural bone healing, which can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the literature as bone morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

The developmental cascade of bone differentiation consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone differentiation activity of bone matrix can be dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi, (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This provides an experimental method for assaying protein extracts for their ability to induce endochondral bone in vivo.

This putative bone inductive protein has been shown to have a molecular mass of less than 50 kilodaltons (kD). Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595).

The potential utility of these proteins has been widely recognized. It is contemplated that the availability of the pure protein would revolutionize orthopedic medicine, certain types of plastic surgery, and various periodontal and craniofacial reconstructive procedures.

The observed properties of these protein fractions have induced an intense research effort in various laboratories directed to isolating and identifying the pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from mammalian bone is disclosed by Sampath et al. (Proc. Natl. Acad. Sci. USA (1987) 80). Urist et al. (Proc. Soc. Exp. Biol. Med. (1984) 173:194-199) disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

Urist et al. (Proc. Natl. Acad. Sci. USA (1984) 81:371-375) disclose a bovine bone morphogenetic protein extract having the properties of an acidic polypeptide and a molecular weight of approximately 18 kD. The authors reported that the protein was present in a fraction separated by hydroxyapatite chromatography, and that it induced bone formation in mouse hindquarter muscle and bone regeneration in trephine defects in rat and dog skulls. Their method of obtaining the extract from bone results in ill-defined and impure preparations.

European Patent Application Serial No. 148,155, published October 7, 1985, purports to disclose osteogenic proteins derived from bovine, porcine, and human origin. One of the proteins, designated by the inventors as a P3 protein having a molecular weight of 22-24 kD, is said to have been purified to an essentially homogeneous state. This material is reported to induce bone formation when implanted into animals.

International Application No. PCT/087/01537, published January 14, 1988, discloses an impure fraction from bovine bone which has bone induction qualities. The named applicants also disclose putative bone inductive factors produced by recombinant DNA techniques. Four DNA sequences were retrieved from human or bovine genomic or cDNA libraries and apparently expressed in recombinant host cells. While the applicants stated that the expressed proteins may be bone morphogenic proteins, bone induction was not demonstrated. See also Urist et al., EP 0,212,474 entitled Bone Morphogenic Agents.

Wang et al. (Proc. Nat. Acad. Sci. USA (1988) 85: 9484-9488) discloses the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been determined.

Wozney et al. (Science (1988) 242: 1528-1534) discloses the isolation of full-length cDNA's encoding the human equivalents of three polypeptides originally purified from bovine bone. The authors report that each of the three recombinantly expressed human proteins are independently or in combination capable of inducing cartilage formation. No evidence of bone formation is reported.

It is an object of this invention to provide osteogenic devices comprising matrices containing dispersed osteogenic protein capable of bone induction in allogenic and xenogenic implants. Another object is to provide synthetic osteogenic proteins capable of inducing endochondral bone formation in mammals, including humans. Yet another object is to provide genes encoding non-native osteogenic proteins and methods for their production using recombinant DNA tech-

niques. Another object is to provide novel biosynthetic forms of osteogenic proteins and a structural design for novel, functional osteogenic proteins. Another object is to provide methods for inducing cartilage formation.

These and other objects and features of the invention will be apparent from the description, drawings, and claims which follow.

Summary of the Invention

This invention involves osteogenic devices which, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation and bone marrow differentiation. Suitably modified as disclosed herein, the devices also may be used to induce cartilage formation. The devices comprise a carrier material, referred to herein as a matrix, having the characteristics disclosed below, containing dispersed osteogenic protein in the form of a biosynthetic construct.

Key to these developments was the successful preparation of substantially pure osteogenic protein by purification from bone, the elucidation of amino acid sequence and structure data of the native osteogenic protein, and insights involving study of the DNA and amino acid sequences of the natural source product. A protocol was developed which results in retrieval of active, substantially pure osteogenic protein from mammalian bone. Investigation of the properties and structure of the native form osteogenic protein then permitted the inventors to develop a rational design for non-native forms, i.e., forms never before known in nature, capable of inducing bone formation. As far as applicants are aware, the constructs disclosed herein constitute the first instance of the design of a functional, active protein without preexisting knowledge of the active region of a native form nucleotide or amino acid sequence.

A series of consensus DNA sequences were designed with the goal of producing an active osteogenic protein. The sequences were based on partial amino acid sequence data obtained from the naturally sourced product and on observed homologies with unrelated genes reported in the literature, or the sequences they encode, having a presumed or demonstrated developmental function. Several of the biosynthetic consensus sequences have been expressed as fusion proteins in procaryotes, purified, cleaved, refolded, combined with a matrix, implanted in an established animal model, and shown to have endochondral bone-inducing activity. The currently preferred active proteins comprise sequences designated COP5, COP7, COP16, and OP1. The amino acid sequences of these proteins are set forth below.

```

30          1      10      20      30      40
COP5      LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPFPLAD
          50      60      70
          HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
35          80      90      100
          ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

```

```

40          1      10      20      30      40
COP7      LYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
          50      60      70
          HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
          80      90      100
          ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

```

```

          -10
          PKHHSQRARKKNKN
50          1      10      20      30      40
COP16     CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGECPFPLAD
          50      60      70
          HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
          80      90      100
          ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

```

5
 OP1
 1 10 20 30 40
 CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
 10 ISVLYFDDSSNVILKKYRNMVVRACGCH

15 In these sequences and all other amino acid sequences disclosed herein, the dashes (-) are used as fillers only to line up comparable sequences in related proteins, and have no other function. Thus, amino acids 45-50 of COP7, for example, are NHAVV. Also, the numbering of amino acids is selected solely for purposes of facilitating comparisons between sequences. Thus, for example, the DF residues numbered at 9 and 10 of COP5 and COP7 may comprise residues, e.g., 35 and 36, of an osteogenic protein embodying the invention. Various leader or trailer sequences may be attached to the operative active region provided the osteogenic or chondrogenic activity of the protein is not destroyed.

20 Thus, in one aspect, the invention comprises a protein comprising an amino acid sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that it is capable of inducing endochondral bone formation when properly folded and implanted in a mammal in association with a matrix. Some of these sequences induce cartilage, but not bone. Also, the bone forming materials may be used to produce cartilage if implanted in an avascular locus, or if an inhibitor to full bone development is implanted together with the active protein. Thus, in another aspect, the invention
 25 comprises a protein less than about 200 amino acids long (for each chain) including a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that it is capable at least of cartilage formation when properly folded and implanted in a mammal in association with a matrix. The phrase "sufficiently duplicative", as used herein, is used to describe proteins having a degree of homology with the specific sequences disclosed herein and other, different amino acids but which nevertheless exhibit osteogenic or chondrogenic activity.

30 In one preferred aspect, these proteins comprise species of the generic amino acid sequences:

1 10 20 30 40 50
 LXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
 35 60 70 80 90 100
 QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
 or
 40 1 10 20 30 40 50
 CXXXXLXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
 45 60 70 80 90 100
 QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

50 where the letters indicate the amino acid residues of standard single letter code, and the Xs each represent any one of the 22 naturally occurring amino acid residues. Preferred amino acid sequences within the foregoing generic sequences are:

55

```

1      10      20      30      40      50
  LYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
5      K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
      F E K I  DN   L   N S   Q  ITK F P   TL
      A   S   K
      60      70      80      90      100
  QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
10     SI HAI SEQV EP  A  EQMNSLAI FFNDQDK I RK EE T DA H H
      RF   T   S   K DPV V  Y N S   H RN   RS
      N   S                   K       P   E

```

15 and

```

1      10      20      30      40      50
20    CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
      RRRS K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
      KE F E K I  DN   L   N S   Q  ITK F P   TL
      Q   A   S   K
      60      70      80      90      100
25    QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
      SI HAI SEQV EP  A  EQMNSLAI FFNDQDK I RK EE T DA H H
      RF   T   S   K DPV V  Y N S   H RN   RS
      N   S                   K       P   E

```

30

wherein each of the amino acids arranged vertically at each position in the sequence may be used alternatively in various combinations. Note that these generic sequences have 6 and preferably 7 cysteine residues where inter- or intramolecular disulfide bonds can form, and contain other critical amino acids which influence the tertiary structure of the proteins. These generic structural features are found in previously published sequences, none of which have been described as capable of osteogenic activity, and most of which never have been linked with such activity.

40

45

50

55

EP 0 723 013 A2

Particular useful sequences include:

5 Vg1 1 10 20 30 40
 CKKRHLYVEFK-DVGWQNWVIAPOGYMANCYGECPYPLTE
 50 60 70
 ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
 80 90 100
 10 ISMLFYDNNNDNVVLRHYENMAVDECGCR

 DPP 1 10 20 30 40
 CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFPLAD
 50 60 70
 15 HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
 80 90 100
 VAMLYLNDQSTVVLKNYQEMTVVGCGCR

20 CBMP-2a 1 10 20 30 40
 CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
 80 90 100
 25 ISMLYLDENEKVVVLKNYQDMVVEGCGCR

30

35

40

45

50

55

5 CBMP-2b 1 10 20 30 40
CRRHSlyVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
50 60 70
HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
80 90 100
ISMLYLDEYDKVVLKKNYQEMVVEGCGCR

10 CBMP-3 1 10 20 30 40
CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFPMPK
50 60 70
SLKPSN--H-ATIQSIVRAVGVPGIPEPCCVPEKMSS
15 80 90 100
LSILFFDENKNVVLKVYPNMTVESACR

20 COP1 1 10 20 30 40
LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
80 90 100
ISMLYLDENSTVVLKKNYQEMTVVGCGR

25 COP3 1 10 20 30 40
LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
30 80 90 100
ISMLYLDENEKVVLKKNYQEMVVEGCGCR

35 COP4 1 10 20 30 40
LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
80 90 100
ISMLYLDENEKVVLKKNYQEMVVEGCGCR

40

45 Vg1 is a known Xenopus sequence heretofore not associated with bone formation. DPP is an amino acid sequence encoded by a Drosophila gene responsible for development of the dorsoventral pattern. OP1 is a region of a natural sequence encoded by exons of a genomic DNA sequence retrieved by applicants. The CBMPs are amino acid sequences comprising subparts of mammalian proteins encoded by genomic DNAs and cDNAs retrieved by applicants. The COPs are totally biosynthetic protein sequences expressed by novel consensus gene constructs, designed using the criteria set forth herein, and not yet found in nature.

50 These proteins are believed to be dimers. They appear not to be active when reduced. Various combinations of species of the proteins may exist as heterodimers or homodimers. As far as applicants are aware, the COP5, COP7, COP16, and OP1 constructs constitute the first instances of the design of a bioactive protein without preexisting knowledge of the active region of a native form nucleotide or amino acid sequence.

The invention thus provides synthetic osteogenic protein produced using recombinant DNA techniques. The protein may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of native protein, no matter how derived. In view of this disclosure, skilled genetic engineers can design and synthesize genes which encode appropriate amino acid sequences, and then can express them in various types of host cells, including both prokaryotes and eucaryotes, to produce large quantities of active synthetic proteins comprising truncated analogs, mutants, fusion pro-

teins, and other constructs mimicking the biological activity of the native forms and capable of inducing bone formation in mammals including humans.

The synthetic proteins are useful in clinical applications in conjunction with a suitable delivery or support system (matrix). The matrix is made up of particles or porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. The particle size should be within the range of 70 - 850 μm , preferably 70 - 420 μm . It may be fabricated by close packing particulate material into a shape spanning the bone defect, or by otherwise structuring as desired a material that is biocompatible (non-inflammatory) and, biodegradable *in vivo* to serve as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. Currently preferred carriers include particulate, demineralized, guanidine extracted, species-specific (allogenic) bone, and particulate, deglycosylated (or HF treated), protein extracted, demineralized, xenogenic bone. Optionally, such xenogenic bone powder matrices also may be treated with proteases such as trypsin. Other useful matrix materials comprise collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates.

The osteogenic proteins and implantable osteogenic devices enabled and disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial and other skeletal or dental anomalies (Glowacki et al. (1981) *Lancet* 1:959-963). The devices may be used to induce local endochondral bone formation in non-union fractures, and in other clinical applications including periodontal applications where bone formation is required. Another potential clinical application is in cartilage repair, for example, in the treatment of osteoarthritis.

Brief Description of the Drawing

The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:

FIGURE 1 is a comparison of the amino acid sequence of various osteogenic proteins to those of the TGF-beta family. COP1, COP3, COP4, COP5, and COP7 are a family of analogs of synthetic osteogenic proteins developed from the consensus gene that was joined to a leader protein via a hinge region having the sequence D-P-N-G that permitted chemical cleavage at the D-P site (by acid) or N-G (by hydroxylamine) resulting in the release of the analog protein; VGI is a *Xenopus* protein, DPP is a *Drosophila* protein; OP1 is a native osteogenic protein; CBMP2a and 2b, and CBMP3 are subparts of proteins disclosed in PCT application 087/01537; MIS is Mullerian inhibitory substance; and "consensus choices" represent various substitutions of amino acids that may be made at various positions in osteogenic proteins;

FIGURE 2A is an *E. coli* expression vector containing a gene of an osteogenic protein fused to a leader protein;

FIGURE 2B is the DNA sequence comprising a modified trp-LE leader, two Fb domains of protein A, an ASP-PRO cleavage site, and the COP5 sequence;

FIGURES 3A and 3B are photomicrographs of implants showing the histology (day 12) of COP5 active recombinant protein. A is a control (rat matrix alone, 25 mg). B is rat matrix plus COP5, showing +++ cartilage formation and ++ bone formation (see key infra). Similar results are achieved with COP7; and

FIGURE 4 is a schematic representation of the DNA sequence and corresponding amino acid sequence of a consensus gene for osteogenic protein (COP5).

Description

Purification protocols have been developed which enable isolation of the osteogenic protein present in crude protein extracts from mammalian bone. The isolation procedure enables the production of significant quantities of substantially pure osteogenic protein from any mammalian species, provided sufficient amounts of fresh bone from the species is available. The empirical development of the procedure, coupled with the availability of fresh calf bone, enabled isolation of substantially pure bovine osteogenic protein (BOP). BOP has been characterized significantly; its ability to induce cartilage and ultimately endochondral bone growth in cat, rabbit, and rat have been studied; it has been shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone extracts; and it may be used to induce formation of endochondral bone in orthopedic defects including non-union fractures. In its native form it is a glycosylated, dimeric protein. However, it is active in deglycosylated form. It has been partially sequenced.

Elucidation of the amino acid sequence of BOP enabled the construction of a consensus nucleic acid sequence designed as disclosed herein based on the sequence data, inferred codons for the sequences, and observation of partial homology with known genes.

5 These consensus sequences have been refined by comparison with the sequences present in certain regulatory genes from *Drosophila*, *Xenopus*, and human followed by point mutation, expression, and assay for activity. This approach has been successful in producing several active totally synthetic constructs not found in nature (as far as applicants are aware) which have true osteogenic activity.

10 These discoveries enable the construction of DNAs encoding totally novel, non-native protein constructs which individually and combined are capable of producing true endochondral bone. The DNAs may be expressed using well established recombinant DNA technologies in procaryotic or eucaryotic host cells, and the expressed proteins may be oxidized and refolded *in vitro* if necessary for biological activity.

15 The design and production of such biosynthetic proteins, the nature of the matrix, and other material aspects concerning the nature, utility, how to make, and how to use the subject matter claimed herein will be further understood from the following, which constitutes the best method currently known for practicing the various aspects of the invention.

CONSENSUS SEQUENCE DESIGN

20 A synthetic consensus gene shown in FIGURE 4 was designed to encode a consensus protein based on amino acid predictions from homology with the TGF-beta gene family. The designed consensus sequence was then constructed using known techniques involving assembly of oligonucleotides manufactured in a DNA synthesizer.

25 Tryptic peptides derived from Bovine Osteogenic Protein isolated by applicants and sequenced by Edman degradation provided amino acid sequences that showed strong homology with the *Drosophila* DPP protein sequence (as inferred from the gene), the *Xenopus* VG1 protein, and somewhat less homology to inhibin and TGF-beta, as demonstrated below in TABLE 1.

30

35

40

45

50

55

TABLE 1

	<u>protein</u>	<u>amino acid sequence</u>	<u>homology</u>
5	(<u>BOP</u>)	SFDAYYCSGACQFPS	(9/15 matches)
		***** * * *	
	(<u>DPP</u>)	GYDAYYCHGKCPFFL	
10	<hr/>		
	(<u>BOP</u>)	SFDAYYCSGACQFPS	(6/15 matches)
		* * * * *	
15	(<u>Vql</u>)	GYMANICYGECPYPL	
	<hr/>		
	(<u>BOP</u>)	SFDAYYCSGACQFPS	(5/15 matches)
		* * * * *	
20	(<u>inhibin</u>)	GYHANYCEGECPSHI	
	<hr/>		
	(<u>BOP</u>)	SFDAYYCSGACQFPS	(4/15 matches)
		* * * * *	
25	(<u>TGF-beta</u>)	GYHANFCLGPCPYIW	
	<hr/>		
30	(<u>BOP</u>)	K/RACCVPTELSAISMLYLDE	(12/20 matches)
		***** * * * *	
	(<u>Vql</u>)	LPCCVPTKMSPISMLFYDNN	
	<hr/>		
35	(<u>BOP</u>)	K/RACCVPTELSAISMLYLDE	(12/20 matches)
		* * * * *	
	(<u>inhibin</u>)	KSCCVPTKLRPMSMLYYDDG	
40	<hr/>		
	(<u>BOP</u>)	K/RACCVPTELSAISMLYLDE	(6/19 matches)
		**** * *	
45	(<u>TGF-beta</u>)	APCCVPQALEPLPIVYYVG	
	<hr/>		
	(<u>BOP</u>)	K/RACCVPTELSAISMLYLDE	(12/20 matches)
		***** * * * *	
50	(<u>DPP</u>)	KACCVPTQLDSVAMLYLNDQ	

	(BOP)	LYVDF	(5/5 matches)
5	(DPP)	LYVDF	

10	(BOP)	LYVDF	(4/5 matches)
	(Vg1)	LYVEF	
		*** *	
15	(BOP)	LYVDF	(4/5 matches)
	(TGF-beta)	LYIDF	
		** **	
20	(BOP)	LYVDF	(2/5 matches)
	(inhibin)	FFVSF	
		* *	
25			
30			

*-match

In determining an appropriate amino acid sequence of an osteogenic protein (from which the nucleic acid sequence can be determined), the following points were considered: (1) the amino acid sequence determined by Edman degradation of natural source osteogenic protein tryptic fragments is ranked highest as long as it has a strong signal and shows homology or conservative changes when aligned with the other members of the gene family; (2) where the sequence matches for all four proteins, it is used in the synthetic gene sequence; (3) matching amino acids in DPP and Vg1 are used; (4) if Vg1 or DPP diverged but either one were matched by inhibin or by TGF-beta, this matched amino acid is chosen; (5) where all sequences diverged, the DPP sequence is initially chosen, with a later plan of creating the Vg1 sequence by mutagenesis kept as a possibility. In addition, the consensus sequence is designed to preserve the disulfide crosslinking and the apparent structural homology among the related proteins.

RECOMBINANT OSTEOGENIC PROTEIN CONSTRUCTS

This approach resulted in the production of novel recombinant proteins capable of inducing formation of cartilage and endochondral bone comprising a protein structure analogous to or duplicative of the functional domain of the naturally sourced material. The amino acid sequences encoded by the consensus DNA sequences were derived from a family of natural proteins implicated in tissue development. These gene products/proteins are known to exist in active form as dimers and are, in general, processed from a precursor protein to produce an active C-terminal domain of the precursor.

The recombinant osteogenic/chondrogenic proteins are "novel", in the sense that, as far as applicants are aware, they do not exist in nature or, if they do exist, have never before been associated with bone or cartilage formation. The approach to design of these proteins is to employ amino acid sequences, found in the native OP isolates, in polypeptide structures are patterned after certain proteins reported in the literature, or the amino acid sequences inferred from DNAs reported in the literature. Thus, using the design criteria set forth above, and refining the amino acid sequence as more protein sequence information was learned, a series of synthetic proteins were designed with the hope and intent that they might have osteogenic or chondrogenic activity when tested in the bioassay system disclosed below.

It was noted, for example, that DPP from drosophila, VG1 from *Xenopus*, the TGF beta family of proteins, and to a lesser extent, alpha and beta inhibins, had significant homologies with certain of the sequences derived from the naturally sourced OP product. (FIGURE 1.) Study of these proteins led to the realization that a portion of the sequence of

EP 0 723 013 A2

each had a structural similarity observable by analysis of the positional relationship of cysteines and other amino acids which have an important influence on three dimensional protein conformation. It was noted that a region of these sequences had a series of seven cysteines, placed very nearly in the same relative positions, and certain other amino acids in sequence as set forth below:

5

```

      10      20      30      40      50
CXXXXLXVFXDXGWXXWXXXPXGXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
10 QXXVXXNXXXXPXXCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

15 wherein each X independently represents an amino acid. Expression experiments of two of these constructs demonstrate activity. Expression experiments with constructs patterned after this template amino acid sequence with a shorter sequence having only six cysteines also show activity:

```

      10      20      30      40      50
LXVFXDXGWXXWXXXPXGXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
20 QXXVXXNXXXXPXXCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

25

wherein each X independently represents an amino acid. Within these generic structures are a multiplicity of specific sequences which have osteogenic or chondrogenic activity. Preferred structures are those having the amino acid sequence:

30

```

      10      20      30      40      50
CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECFPFLADHLNSTNHAIV
      35  RKRS K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
      KE F E K I  DN  L  N  S  Q  ITK F P  TL
      Q  A  S  K
      60      70      80      90     100
QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
40  SI HAI SEQV EP  A EQMNSLAI FFNDQDK I RK EE T DA H H
      RF  T  S  K DPV V  Y N S  H RN  RS
      N  S  K  P  E

```

45 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be used. Novel active proteins also are defined by amino acid sequences comprising an active domain beginning at residue number 6 of this sequence, i.e. omitting the N terminal CXXXX, or omitting any of the preferred specific combinations such as CKRHP, CRRKQ, CKRHE, etc. resulting in a construct having only six cysteine residues. After this work, PCT 87/01537 was published, and it was observed that the proteins there identified as BMPII a and b and BMPIII each included a region embodying this generic structure. These proteins were not demonstrated to be osteogenic in the published application. However, applicants discovered that a subpart of the amino acid sequence of these proteins, properly folded, and implanted as set forth herein, is active. These are disclosed herein as CBMPIIa, CBMPIIb, and CBMPIII. Also, applicants retrieved a previously unreported gene by probing a human genomic DNA library with COPO. This protein was designated OP1. It comprises a region exhibiting the same generic structure.

55 Thus, the preferred osteogenic proteins are expressed from recombinant DNA and comprise amino acid sequences including any of the following sequences:

EP 0 723 013 A2

5 Vg1 1 10 20 30 40
CKKRHLYVEFK-DVGWQNWVIAPOGYMANYCYGECPYPLTE
50 60 70
ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
80 90 100
ISMLFYDNNNDNVVLRHYENMAVDECGCR

10 DPP 1 10 20 30 40
CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFPLAD
50 60 70
HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
15 80 90 100
VAMLYLNDQSTVVLKQEMTVVGCGCR

20 OP1 1 10 20 30 40
LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
25 80 90 100
ISVLYFDDSSNVILKKYRNMVVVRACGCH

30

35

40

45

50

55

EP 0 723 013 A2

-5
HQRQA

5 OP1 1 10 20 30 40
CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
 50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
10 ISVLYFDDSSNVILKKYRNMVVRACGCH

 1 10 20 30 40
CBMP-2a CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
 50 60 70
15 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
 80 90 100
ISMLYLDENEKVVVKNYQDMVVEGCGCR

 1 10 20 30 40
CBMP-2b CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPPFLAD
 50 60 70
20 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
 80 90 100
25 ISMLYLDYDKVVLKQEMVVEGCGCR

 1 10 20 30 40
CBMP-3 CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFPMPK
 50 60 70
30 SLKPSN--H-ATIQSIVRAVGVPGIPEPCCVPEKMSS
 80 90 100
LSILFFDENKNVVLKVYPNMTVESCACR

 1 10 20 30 40
COP1 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 60 70
35 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
 80 90 100
40 ISMLYLDENSTVVLKQEMTVVGCGCR

 1 10 20 30 40
COP3 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
45 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
 80 90 100
50 ISMLYLDENEKVVVKNYQEMVVEGCGCR

55

1 10 20 30 40
 COP4 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 5 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR
 10
 1 10 20 30 40
 COP5 LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 15 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR
 20
 1 10 20 30 40
 COP7 LYVDFS-DVGWDDWIVAPPGYHAFYCHGECPPFLAD
 50 60 70
 HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR
 25
 10
 PKHHSQRARKKNKN
 1 10 20 30 40
 COP16 CRRHS LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
 30 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR
 35

As shown in FIGURE 1, these sequences have considerable homology with the alpha and beta inhibins, three forms of TGF beta, and MIS.

40 Gene Preparation

The synthetic genes designed to express the proteins as described above preferably are produced by assembly of chemically synthesized oligonucleotides. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer (TBE). The DNA is then electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE. Natural gene sequences and cDNAs also may be used for expression.

Expression

The genes can be expressed in appropriate prokaryotic hosts such as various strains of *E. coli* and also in bacillus, yeasts, and various animal cells such as CHO, myeloma, etc. Generally, expression may be achieved using many cell types and expression systems well known to those skilled in the art. If the gene is to be expressed in *E. coli*, it must first be cloned into an expression vector. An expression vector (FIGURE 2A) based on pBR322 and containing a synthetic trp promoter operator and the modified trp LE leader can be opened at the EcoRI and PSTI restriction sites, and a FB-
55 FB COP1, COP3, COP5, and COP7 gene fragments (FIGURE 2B) can be inserted between these sites, where FB is fragment B of Staphylococcal Protein A. The expressed fusion protein results from attachment of the COP gene to a fragment encoding FB. The COP protein is joined to the leader protein via a hinge region having the sequence Asp-Pro-Asn-Gly. This hinge permits chemical cleavage of the fusion protein with dilute acid at the asp-pro site or cleavage at

Asn-Gly with hydroxylamine, resulting in release of the COP protein. For COP16 and OP1, the proteins are expressed as fusion products, using the modified trp-LE as a leader,

Production of Active Proteins

5

The following procedure was followed for production of active recombinant proteins. *E. coli* cells containing the fusion proteins were lysed. The fusion proteins were purified by differential solubilization. In the case of the COP1, 3, 4, 5, and 7 fusion proteins, cleavage was with dilute acid, and the resulting cleavage products were passed through a Sephacryl-200HR column. The Sephacryl column separated most of the uncleaved fusion products from the COP1, 3, 4, 5, and 7 analogs. In the case of the COP16 or OP1 fusion protein, cleavage was with a more concentrated acid, and an SP-Trisacryl column was used as an additional purification step. The COP or OP fractions were then subjected to HPLC on a semi-prep C-18 column.

Initial conditions for refolding of COP analogs or OP1 were at pH 8.0 using Tris, Gu-HCl, dithiothreitol. Final conditions for refolding of COP analogs were at pH 8.0 using Tris, oxidized glutathione, and lower amounts of Gu-HCl and dithiothreitol. Alternatively, the COP or OP1 proteins are suspended in 50 mM HCl, 6 M guanidine-HCl, pH 8.0, for 18 hours at 4°C. Refolding may not be required if the proteins are expressed in animal cells.

Production of Antisera

Antisera to COP7 and COP5 were produced in New Zealand white rabbits. Western blots demonstrate that the antisera react with COP7 and COP5 preparations. Antisera to COP7 has been tested for reactivity to naturally sourced bovine osteogenic protein samples. Western blots show a clear reaction with the 30 kD protein and, when reduced, with the 16 kD subunit. The immunoreactive species appears as a closely-spaced doublet in the 16 kD subunit region, similar to the 16 kD doublet seen in Con A blots.

25

MATRIX PREPARATION

General Consideration of Matrix Properties

The carrier described in the bioassay section, *infra*, may be replaced by either a biodegradable-synthetic or synthetic-inorganic matrix (e.g., HAP, collagen, tricalcium phosphate, or polylactic acid, polyglycolic acid and various copolymers thereof). Also xenogeneic bone may be used if pretreated as described below.

Studies have shown that surface charge, particle size, the presence of mineral, and the methodology for combining matrix and osteogenic protein all play a role in achieving successful bone induction. Perturbation of the charge by chemical modification abolishes the inductive response. Particle size influences the quantitative response of new bone; particles between 75 and 420 µm elicit the maximum response. Contamination of the matrix with bone mineral will inhibit bone formation. Most importantly, the procedures used to formulate osteogenic protein onto the matrix are extremely sensitive to the physical and chemical state of both the osteogenic protein and the matrix.

The sequential cellular reactions at the interface of the bone matrix/OP implants are complex. The multistep cascade includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

A successful carrier for osteogenic protein must perform several important functions. It must bind osteogenic protein and act as a slow release delivery system, accommodate each step of the cellular response during bone development, and protect the osteogenic protein from nonspecific proteolysis. In addition, selected materials must be biocompatible *in vivo* and biodegradable; the carrier must act as a temporary scaffold until replaced completely by new bone. Biocompatibility requires that the matrix not induce significant inflammation when implanted and not be rejected by the host animal. Biodegradability requires that the matrix be slowly absorbed by the body of the host during development of new bone or cartilage. Polylactic acid (PLA), polyglycolic acid (PGA), and various combinations have different dissolution rates *in vivo*. In bones, the dissolution rates can vary according to whether the implant is placed in cortical or trabecular bone.

Matrix geometry, particle size, the presence of surface charge, and porosity or the presence of interstices among the particles of a size sufficient to permit cell infiltration, are all important to successful matrix performance. It is preferred to shape the matrix to the desired form of the new bone and to have dimensions which span non-union defects. Rat studies show that the new bone is formed essentially having the dimensions of the device implanted.

The matrix may comprise a shape-retaining solid made of loosely adhered particulate material, e.g., with collagen. It may also comprise a molded, porous solid, or simply an aggregation of close-packed particles held in place by surrounding tissue. Masticated muscle or other tissue may also be used. Large allogeneic bone implants can act as a carrier for the matrix if their marrow cavities are cleaned and packed with particles and the dispersed osteogenic protein.

Preparation of Biologically Active Allogenic Matrix

Demineralized bone matrix is prepared from the dehydrated diaphyseal shafts of rat femur and tibia as described herein to produce a bone particle size which pass through a 420 μm sieve. The bone particles are subjected to dissociative extraction with 4 M guanidine-HCl. Such treatment results in a complete loss of the inherent ability of the bone matrix to induce endochondral bone differentiation. The remaining insoluble material is used to fabricate the matrix. The material is mostly collagenous in nature, and upon implantation, does not induce cartilage and bone. All new preparations are tested for mineral content and false positives before use. The total loss of biological activity of bone matrix is restored when an active osteoinductive protein fraction or a pure protein is reconstituted with the biologically inactive insoluble collagenous matrix. The osteoinductive protein can be obtained from any vertebrate, e.g., bovine, porcine, monkey, or human, or produced using recombinant DNA techniques.

Preparation of Deglycosylated Bone Matrix for Use in Xenogenic Implant

When osteogenic protein is reconstituted with collagenous bone matrix from other species and implanted in rat, no bone is formed. This suggests that while the osteogenic protein is xenogenic (not species specific), while the matrix is species specific and cannot be implanted cross species perhaps due to intrinsic immunogenic or inhibitory Components. Thus, heretofore, for bone-based matrices, in order for the osteogenic protein to exhibit its full bone inducing activity, a species specific collagenous bone matrix was required.

The major component of all bone matrices is Type I collagen. In addition to collagen, extracted bone includes non-collagenous proteins which may account for 5% of its mass. Many non-collagenous components of bone matrix are glycoproteins. Although the biological significance of the glycoproteins in bone formation is not known, they may present themselves as potent antigens by virtue of their carbohydrate content and may constitute immunogenic and/or inhibitory components that are present in xenogenic matrix.

It has now been discovered that a collagenous bone matrix may be used as a carrier to effect bone inducing activity in xenogenic implants, if one first removes the immunogenic and inhibitory components from the matrix. The matrix is deglycosylated chemically using, for example, hydrogen fluoride to achieve this purpose.

Bovine bone residue prepared as described above is sieved, and particles of the 74-420 μm are collected. The sample is dried in vacuo over P_2O_5 , transferred to the reaction vessel and anhydrous hydrogen fluoride (HF) (10-20 ml/g of matrix) is then distilled onto the sample at -70°C . The vessel is allowed to warm to 0°C . and the reaction mixture is stirred at this temperature for 120 min. After evaporation of the HF in vacuo, the residue is dried thoroughly in vacuo over KOH pellets to remove any remaining traces of acid.

Extent of deglycosylation can be determined from carbohydrate analysis of matrix samples taken before and after treatment with HF, after washing the samples appropriately to remove non-covalently bound carbohydrates.

The deglycosylated bone matrix is next treated as set forth below:

1) suspend in TBS (Tris-buffered Saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS) and stir at RT for 30 min;

2) centrifuge and wash with TBS or UTBS as in step 1; and

3) centrifuge; discard supernatant; water wash residue; and then lyophilize.

FABRICATION OF DEVICE

Fabrication of osteogenic devices using any of the matrices set forth above with any of the osteogenic proteins described above may be performed as follows.

A. Ethanol precipitation

In this procedure, matrix is added to osteogenic protein in guanidine-HCl. Samples are vortexed and incubated at a low temperature. Samples are then further vortexed. Cold absolute ethanol is added to the mixture which is then stirred and incubated. After centrifugation (microfuge high speed) the supernatant is discarded. The reconstituted matrix is washed with cold concentrated ethanol in water and then lyophilized,

B. Acetonitrile Trifluoroacetic Acid Lyophilization

In this procedure, osteogenic protein in an acetonitrile trifluoroacetic acid (ACN/TFA) solution is added to the carrier. Samples are vigorously vortexed many times and then lyophilized.

C. Urea Lyophilization

For those proteins that are prepared in urea buffer, the protein is mixed with the matrix, vortexed many times, and then lyophilized. The lyophilized material may be used "as is" for implants.

IN VIVO RAT BIOASSAY

Several of the synthetic proteins have been incorporated in matrices to produce osteogenic devices, and assayed in rat for endochondral bone. Studies in rats show the osteogenic effect to be dependent on the dose of osteogenic protein dispersed in the osteogenic device. No activity is observed if the matrix is implanted alone. The following sets forth guidelines for how the osteogenic devices disclosed herein can be assayed for evaluating protein constructs and matrices for biological activity.

A. Subcutaneous Implantation

The bioassay for bone induction as described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80: 6591-6595), herein incorporated by reference, is used to assess endochondral bone differentiation activity. This assay consists of implanting the test samples in subcutaneous sites in allogenic recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is designated as day one of the experiment. Implants were removed on day 12. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.

B. Cellular Events

The implant model in rats exhibits a controlled progression through the stages of matrix induced endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

C. Histological Evaluation

Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Implants are fixed in Bouins Solution, embedded in parafilm, cut into 6-8 mm sections. Staining with toluidine blue or hematoxylin/eosin demonstrates clearly the ultimate development of endochondral bone. Twelve day implants are usually sufficient to determine whether the implants show bone inducing activity.

D. Biological Markers

Alkaline phosphatase activity may be used as a marker for osteogenesis. The enzyme activity may be determined Spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Implants showing no bone development by histology should have little or no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation very quickly after the implants are removed from the rat. Alternatively the amount of bone formation can be determined by measuring the calcium content of the implant.

The osteogenic activity due to osteogenic protein is represented by "bone forming units". One bone forming unit represents the amount of protein that is needed for half maximal bone forming activity as compared to rat demineralized bone matrix as control and determined by calcium content of the implant on day 12.

Devices that contained only rat carrier show complete absence of new bone formation. The implant consists of carrier rat matrix and surrounding mesenchymal cells. Again, the devices that contained rat carrier and not correctly folded (or biologically inactive) recombinant protein also showed complete absence of bone formation. These implants are scored as cartilage formation (-) and bone formation (-). The endochondral bone formation activity is scored as zero percent (0%) (FIGURE 3A).

Implants included biologically active recombinant protein, however, showed evidence of endochondral bone formation. Histologically they showed new cartilage and bone formation.

The cartilage formation is scored as (+) by the presence of metachromatically stained chondrocytes in the center of the implant, as (++) by the presence of numerous chondrocytes in many areas of the implant and as (+++) by the presence of abundant chondrocytes forming cartilage matrix and the appearance of hypertrophied chondrocytes accompanying cartilage calcification (FIGURE 3B).

The bone formation is scored as (+) by the presence of osteoblast surrounding vascular endothelium forming new matrix, as (++) by the formation of bone due to osteoblasts (as indicated by arrows) and further bone remodeling by the appearance of osteoclasts in opposition to the newly formed bone matrix. Vascular invasion is evident in these implants (FIGURE 3B). Formation is scored as (+++) by the presence of extensive remodeled bone which results in the formation of ossicles.

The overall bone inducing activity due to recombinant protein is represented as percent response of endochondral bone formation (see TABLE 2 below).

TABLE 2

HISTOLOGICAL EVALUATION OF RECOMBINANT BONE INDUCTIVE PROTEINS			
Sample No.	Implanted Protein	Cartilage Formation	Bone Formation
260-54	COP-5	+++	++
279-5	COP-5	++	+
285-13	COP-5	+++	++
277-7	COP-7	+++	++
277-8	COP-7	+++	++
277-9	COP-7	++	+
285-14	COP-7	+++	++
285-24	COP-7	++	+
285-25	COP-7	++	++
314-6	COP-16	+++	+++
314-15	COP-16	++	+
314-16	COP-16	++	+
314-12	OP-1	++	+

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

The invention relates to an osteogenic device for implantation in a mammal, said device comprising a biocompatible, *in vivo* biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains, each of which comprises an amino acid sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing endochondral bone formation in association with said matrix when implanted in a mammal.

Also covered by the invention is a device for implantation in a mammal, said device comprising a biocompatible, *in vivo* biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains, each of which has less than about 200 amino acids, and each of which comprises a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing cartilage formation in association with said matrix when implanted in a mammal.

EP 0 723 013 A2

The sequence may comprise

```

      10      20      30      40      50
5  CXXXLXVXFXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
    QXXVXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
  
```

10 wherein each X independently represents an amino acid; or

```

      10      20      30      40      50
15 LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
    QXXVXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
  
```

20 wherein each X independently represents an amino acid; or

```

      10      20      30      40      50
25 CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIV
    RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
      KE F E K I DN L N S Q ITK F P TL
      Q A S K
      60      70      80      90     100
30 QTLVNSVNPGKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGR
    SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
      RF T S K DPV V Y N S H RN RS
      N S K P E
  
```

35 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

```

      10      20      30      40      50
40 LYVDFRDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIV
    K S S L QE VIS E FD Y E A AY MPESMKAS VI
      F E K I DN L N S Q ITK F P TL
      A S K
      60      70      80      90     100
45 QTLVNSVNPGKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGR
    SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
      RF T S K DPV V Y N S H RN RS
      N S K P E
50
  
```

55 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

EP 0 723 013 A2

5 Vg1 1 10 20 30 40
CKKRHLVVEFK-DVGWQNWVIA PQGYMANYCYGEC PYPLTE
50 60 70
ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
80 90 100
ISMLFYDNNNDNVVLRHYENMAVDECGCR

10

or

15

DPP 1 10 20 30 40
CRRHSLYVDFS-DVGWDDWIVAPLG YDAYYCHGKCPFPLAD
50 60 70
HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
20 80 90 100
VAMLYLNDQSTVVVLKQEMTVVGCGR

25

or

30

35 OP1 1 10 20 30 40
LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFP LNS
50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
80 90 100
ISVLYFDDSSNVILKKYRNMVVVRACGCH

40

45

50

55

EP 0 723 013 A2

or

5
-5
HQRQA
OP1 1 10 20 30 40
CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPFLNS
50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
10 80 90 100
ISVLYFDDSSNVILKKYRNMVVRACGCH

15

or

20
25
CBMP-2a 1 10 20 30 40
CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
50 60 70
HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
30 80 90 100
ISMLYLDENEKVVLKQDMVVEGCGCR

35

or

40
45
CBMP-2b 1 10 20 30 40
CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPPFLAD
50 60 70
HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
50 80 90 100
ISMLYLDEYDKVVLKQEMVVEGCGCR

55

or

5

10 CBMP-3 1 10 20 30 40
CARRYLKVDFA-DIGWSEWII SPKSF DAYYCSGACQFPMPK
50 60 70
SLKPSN--H-ATIQSIVRAVG VVPGIPEPCCVPEKMSS
80 90 100
LSILFFDENKNVVLKVYPNMTVESACR

15

20

or

25

30 COP1 1 10 20 30 40
LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNP GK-VPKPCCVPTELSA
80 90 100
ISMLYLDENSTVVLKKNYQEMTVVGCGCR

35

40

or

45 COP3 1 10 20 30 40
LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNP GK-VPKPCCVPTELSA
80 90 100
ISMLYLDENEKVVLKKNYQEMVVEGCGCR

50

55

or

5 1 10 20 30 40
 COP4 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPVK-VPKPCCVPTELSA
 80 90 100
 10 ISMLYLDENEKVVLKKNYQEMVVEGCGCR

or

15 1 10 20 30 40
 COP5 LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
 50 60 70
 20 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
 80 90 100
 ISMLYLDENEKVVLKKNYQEMVVEGCGCR

or

25 1 10 20 30 40
 COP7 LYVDFS-DVGWDDWIVAPPGYHAFYCHGECPPFLAD
 50 60 70
 30 HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
 80 90 100
 ISMLYLDENEKVVLKKNYQEMVVEGCGCR

or

35 10
 PKHHSQRARKKNKN
 40 1 10 20 30 40
 COP16 CRRHSLYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
 80 90 100
 45 ISMLYLDENEKVVLKKNYQEMVVEGCGCR

The device of the invention may comprise an osteogenic protein comprising a pair of separate polypeptide chains.

50 The invention also relates to an osteogenic protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains each of which comprises a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing endochondral bone formation in association with a matrix when implanted in a mammal.

55 In another embodiment, the invention relates to a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains less than about 200 amino acids long and comprising a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing cartilage formation in association with a matrix when implanted in a mammal.

EP 0 723 013 A2

The protein may be unglycosylated, and may comprise the amino acid sequences:

```

      10      20      30      40      50
5  CXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNHAXX
      60      70      80      90     100
   QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

10 or

```

      10      20      30      40      50
   LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNHAXX
      60      70      80      90     100
15 QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

wherein each X independently represents an amino acid.

20 The protein of the invention may comprise the amino acid sequences:

```

      10      20      30      40      50
   CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
25  RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
      KE F E K I DN L N S Q ITK F P TL
      Q A S K
      60      70      80      90     100
   QTLVNSVNPFGKIPKACCVPTLSAISMLYLDENENVVLKKNYQDMVVEGCGCR
30  SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
      RF T S K DPV V Y N S H RN RS
      N S K P E

```

35 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position.

The protein of the invention may comprise the amino acid sequences:

```

      10      20      30      40      50
   LYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
40  K S S L QE VIS E FD Y E A AY MPESMKAS VI
      F E K I DN L N S Q ITK F P TL
      A S K
45      60      70      80      90     100
   QTLVNSVNPFGKIPKACCVPTLSAISMLYLDENENVVLKKNYQDMVVEGCGCR
   SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
      RF T S K DPV V Y N S H RN RS
50  N S K P E

```

55 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position.

EP 0 723 013 A2

The protein of the invention may comprise the amino acid sequences:

5 Vg1 1 10 20 30 40
CKKRHLYVEFK-DVGWQNWVIAPQGYMANYCYGECPYPLTE
50 60 70
ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
80 90 100
ISMLFYDNNNDNVVLRHYENMAVDECGCR

10 or

15 DPP 1 10 20 30 40
CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFPLAD
50 60 70
HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
80 90 100
VAMLYLNDQSTVVLKNYQEMTVVGCGR

20 or

25 OP1 1 10 20 30 40
LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
80 90 100
30 ISVLYFDDSSNVILKKYRNMVVRACGCH

or

35 OP1 1 10 20 30 40
CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
80 90 100
ISVLYFDDSSNVILKKYRNMVVRACGCH

45 or

50 CBMP-2a 1 10 20 30 40
CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
50 60 70
HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA
80 90 100
ISMLYLDENEKVVVLKNIQDMVVEGCGCR

55

EP 0 723 013 A2

or

5 CBMP-2b 1 10 20 30 40
CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
50 60 70
HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA
80 90 100
10 ISMLYLDEYDKVVLKKNYQEMVVEGCGCR

or

15 CBMP-3 1 10 20 30 40
CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFPMPK
50 60 70
SLKPSN--H-ATIQSIVRAVGVPPIPEPCCVPEKMSS
20 80 90 100
LSILFFDENKNVVLKVYPNMTVESACR

25 or

30 COP1 1 10 20 30 40
LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
80 90 100
ISMLYLDENSTVVLKKNYQEMTVVGCGR

35

or

40 COP3 1 10 20 30 40
LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
45 80 90 100
ISMLYLDENKVLKKNYQEMVVEGCGCR

50

55

or

5
COP4 1 10 20 30 40
LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
80 90 100
10 ISMLYLDENEKVVVLKNYQEMVVEGCGCR

or

15
COP5 1 10 20 30 40
LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
50 60 70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
20 ISMLYLDENEKVVVLKNYQEMVVEGCGCR

or

25
COP7 1 10 20 30 40
LYVDFS-DVGWDDWIVAPPGYHAFYCHGECPPFLAD
50 60 70
HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
30 ISMLYLDENEKVVVLKNYQEMVVEGCGCR

or

35
COP16 1 10 20 30 40
CRRHSLYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
50 60 70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
40 ISMLYLDENEKVVVLKNYQEMVVEGCGCR

45

The protein of the invention may comprise the product of expression of a DNA in a procaryotic cell.

Also contemplated by the invention is a cell line engineered to express the protein of the invention.

Preferably, the protein has a half maximum bone forming activity of about 20-25 ng per 25 mg of implant.

The invention also contemplates antibodies reactive with an epitope of the protein of the invention.

50

The device of the invention preferably includes a matrix comprising demineralized, deglycosylated, protein extracted, particulate, xenogenic bone, or demineralized, protein extracted, particulate, xenogenic bone treated with HF.

Claims

- 55 1. A process for producing active synthetic osteogenic protein, said protein comprising a pair of polypeptide chains disulphide bonded to produce a dimeric species, the process comprising the steps of:

(a) producing a consensus amino acid sequence by comparing amino acid sequences of proteins of the TGF-beta gene family;

- (b) constructing a synthetic gene encoding the consensus amino acid sequence of step (a), for example by assembling chemically synthesised oligonucleotides;
 (c) introducing the synthetic gene of step (b) into a prokaryotic or eukaryotic host cell;
 (d) expressing the synthetic gene to produce a putative synthetic osteogenic protein;
 5 (e) assaying the putative synthetic osteogenic protein to determine whether it is active in inducing endochondral bone formation when implanted in a mammal, and
 (f) repeating steps (a) to (e) (or mutagenizing the synthetic gene and repeating steps (c) to (e)) if the putative synthetic osteogenic protein is inactive when so assayed.
- 10 2. The process of claim 1 wherein in step (a) the consensus nucleic acid sequence substantially preserves the disulphide crosslinking pattern present in the sequence:

(a)

15 **LXVXFDXGWXXWXXXPXGXXAXYCXXGXCXXPXXXXXXXXXXNHAXXQX**
XVXXNXXXXPXXCCPXXXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXC
 20 **XCX; or**

(b)

25 **CXXXXLXVXFDXGWXXWXXXPXGXXAXYCXXGXCXXPXXXXXXXXXXNH**
 30 **AXXQXXVXXNXXXXPXXCCPXXXXXXXXXXLXXXXXXXXVXLXXYXXM**
XVXXCXCX;

35 wherein the letters indicate the amino acid residues of standard single letter code and each X represents any amino acid.

- 40 3. The process of any one of the preceding claims wherein the consensus nucleic acid sequence comprises the sequence:

(a)

45 **LXVXFDXGWXXWXXXPXGXXAXYCXXGXCXXPXXXXXXXXXXNHAXXQX**
XVXXNXXXXPXXCCPXXXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXC
 50 **XCX; or**

(b)

CXXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNH
 5 AXXQXXVXXXXXNXXXPXXCCPXXXXXXXXXXLXXXXXXXXVXLXXYXXM
 XVXXCXCX;

10

wherein the letters indicate the amino acid residues of standard single letter code and each X represents any amino acid.

4. The process of any one of the preceding claims wherein the synthetic gene of step (b) comprises a nucleotide
 15 sequence which encodes a synthetic polypeptide chain having the same number of cysteine residues in the same relative positions as COP5, COP7, COP16 or OP1.
5. The process of any one of the preceding claims wherein the synthetic gene of step (b) comprises a nucleotide
 20 sequence which encodes a synthetic polypeptide chain sharing one or more amino acids at corresponding positions in any of the sequences: Vg1, DPP, OP1, CBMP-2a, CBMP-2b, CBMP-3, COP1, COP3, COP4, COP5, COP7 or COP16.
6. The process of any one of the preceding claims wherein the synthetic gene of step (b) comprises a nucleotide
 25 sequence which encodes a synthetic polypeptide chain comprising the amino acid sequence:

(a)

10 20 30 40 50
 CKRHPLYVDFRDVGWNDWIVPPGYHAFYCHGECPPFLADHLNSTNHAIV
 30 RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
 KE F E K I DN L N S Q ITK F P TL
 Q A S K
 60 70 80 90 100
 35 QTLVNSVNPFGKIPKACCVPTLSAISMVLYLDENENVVLKKNYQDMVVEGCGCR
 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 N S K P E

40

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

(b)

10 20 30 40 50
 LYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
 50 K S S L QE VIS E FD Y E A AY MPESMKAS VI
 F E K I DN L N S Q ITK F P TL
 A S K
 60 70 80 90 100
 55 QTLVNSVNPFGKIPKACCVPTLSAISMVLYLDENENVVLKKNYQDMVVEGCGCR
 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S X DPV V Y N S H RN RS
 N S K P E

EP 0 723 013 A2

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

(c)

5

10

```

1      10      20      30      40
CKKRHLVVEFK-DVGWQNWVIA PQGYMANYCYGEC PYPLTE
           50      60      70
ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
           80      90     100
ISMLFYDNNNDNVVLRHYENMAVDECGCR; or

```

15

(d)

20

25

```

1      10      20      30      40
CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFLAD
           50      60      70
HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
           80      90     100
VAMLYLNDQSTVVLKNYQEMTVVGCGR; or

```

30

(e)

35

40

```

1      10      20      30      40
      LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFFLNS
           50      60      70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
           80      90     100
ISVLYFDDSSNVILKKYRNMVVRACGCH; or

```

(f)

45

50

55

```

                                           -5
                                           HQRQA
1      10      20      30      40
CKKBELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFFLNS
           50      60      70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
           80      90     100
ISVLYFDDSSNVILKKYRNMVVRACGCH; or

```

(g)

1 10 20 30 40
 5 CKRREPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
 80 90 100
 10 ISMLYLDENEKVVVLKQDMVVEGCGCR; or

(h)

1 10 20 30 40
 15 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPPFLAD
 50 60 70
 20 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
 80 90 100
 ISMLYLDDEYDKVVVLKQEMVVEGCGCR; or

(i)

1 10 20 30 40
 30 CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFPMPK
 50 60 70
 SLKPSN--H-ATIQSIVRAVGVPGEPECCVPERMSS
 80 90 100
 35 LSILFFDENKNVVLKVYPNMTVESCACR; or

(j)

1 10 20 30 40
 45 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPVK-VPKPCCVPTELSA
 80 90 100
 50 ISMLYLDENSTVVVLKQEMTVVGCGR; or

55

(k)

1 10 20 30 40
 5 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPF SAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNP GK-VPKPCCVPTLSA
 80 90 100
 10 ISMLYLDENEKVV LKNYQEMVVEGCGCR; or

(l)

1 10 20 30 40
 15 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPF SAD
 50 60 70
 20 HFNSTN--H-AVVQTLVNNMNP GK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVV LKKYQEMVVEGCGCR; or

(m)

1 10 20 30 40
 30 LYVDFS-DVGWDDWIVAPPGYQAFYCHGECFPF LAD
 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 35 ISMLYLDENEKVV LKNYQEMVVEGCGCR; or

(n)

1 10 20 30 40
 40 LYVDFS-DVGWDDWIVAPPGYHAFYCHGECFPF LAD
 50 60 70
 45 HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 ISMLYLDENEKVV LKNYQEMVVEGCGCR; or

(o)

55

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460
 465
 470
 475
 480
 485
 490
 495
 500
 505
 510
 515
 520
 525
 530
 535
 540
 545
 550
 555
 560
 565
 570
 575
 580
 585
 590
 595
 600
 605
 610
 615
 620
 625
 630
 635
 640
 645
 650
 655
 660
 665
 670
 675
 680
 685
 690
 695
 700
 705
 710
 715
 720
 725
 730
 735
 740
 745
 750
 755
 760
 765
 770
 775
 780
 785
 790
 795
 800
 805
 810
 815
 820
 825
 830
 835
 840
 845
 850
 855
 860
 865
 870
 875
 880
 885
 890
 895
 900
 905
 910
 915
 920
 925
 930
 935
 940
 945
 950
 955
 960
 965
 970
 975
 980
 985
 990
 995
 1000
 1005
 1010
 1015
 1020
 1025
 1030
 1035
 1040
 1045
 1050
 1055
 1060
 1065
 1070
 1075
 1080
 1085
 1090
 1095
 1100
 1105
 1110
 1115
 1120
 1125
 1130
 1135
 1140
 1145
 1150
 1155
 1160
 1165
 1170
 1175
 1180
 1185
 1190
 1195
 1200
 1205
 1210
 1215
 1220
 1225
 1230
 1235
 1240
 1245
 1250
 1255
 1260
 1265
 1270
 1275
 1280
 1285
 1290
 1295
 1300
 1305
 1310
 1315
 1320
 1325
 1330
 1335
 1340
 1345
 1350
 1355
 1360
 1365
 1370
 1375
 1380
 1385
 1390
 1395
 1400
 1405
 1410
 1415
 1420
 1425
 1430
 1435
 1440
 1445
 1450
 1455
 1460
 1465
 1470
 1475
 1480
 1485
 1490
 1495
 1500
 1505
 1510
 1515
 1520
 1525
 1530
 1535
 1540
 1545
 1550
 1555
 1560
 1565
 1570
 1575
 1580
 1585
 1590
 1595
 1600
 1605
 1610
 1615
 1620
 1625
 1630
 1635
 1640
 1645
 1650
 1655
 1660
 1665
 1670
 1675
 1680
 1685
 1690
 1695
 1700
 1705
 1710
 1715
 1720
 1725
 1730
 1735
 1740
 1745
 1750
 1755
 1760
 1765
 1770
 1775
 1780
 1785
 1790
 1795
 1800
 1805
 1810
 1815
 1820
 1825
 1830
 1835
 1840
 1845
 1850
 1855
 1860
 1865
 1870
 1875
 1880
 1885
 1890
 1895
 1900
 1905
 1910
 1915
 1920
 1925
 1930
 1935
 1940
 1945
 1950
 1955
 1960
 1965
 1970
 1975
 1980
 1985
 1990
 1995
 2000
 2005
 2010
 2015
 2020
 2025
 2030
 2035
 2040
 2045
 2050
 2055
 2060
 2065
 2070
 2075
 2080
 2085
 2090
 2095
 2100
 2105
 2110
 2115
 2120
 2125
 2130
 2135
 2140
 2145
 2150
 2155
 2160
 2165
 2170
 2175
 2180
 2185
 2190
 2195
 2200
 2205
 2210
 2215
 2220
 2225
 2230
 2235
 2240
 2245
 2250
 2255
 2260
 2265
 2270
 2275
 2280
 2285
 2290
 2295
 2300
 2305
 2310
 2315
 2320
 2325
 2330
 2335
 2340
 2345
 2350
 2355
 2360
 2365
 2370
 2375
 2380
 2385
 2390
 2395
 2400
 2405
 2410
 2415
 2420
 2425
 2430
 2435
 2440
 2445
 2450
 2455
 2460
 2465
 2470
 2475
 2480
 2485
 2490
 2495
 2500
 2505
 2510
 2515
 2520
 2525
 2530
 2535
 2540
 2545
 2550
 2555
 2560
 2565
 2570
 2575
 2580
 2585
 2590
 2595
 2600
 2605
 2610
 2615
 2620
 2625
 2630
 2635
 2640
 2645
 2650
 2655
 2660
 2665
 2670
 2675
 2680
 2685
 2690
 2695
 2700
 2705
 2710
 2715
 2720
 2725
 2730
 2735
 2740
 2745
 2750
 2755
 2760
 2765
 2770
 2775
 2780
 2785
 2790
 2795
 2800
 2805
 2810
 2815
 2820
 2825
 2830
 2835
 2840
 2845
 2850
 2855
 2860
 2865
 2870
 2875
 2880
 2885
 2890
 2895
 2900
 2905
 2910
 2915
 2920
 2925
 2930
 2935
 2940
 2945
 2950
 2955
 2960
 2965
 2970
 2975
 2980
 2985
 2990
 2995
 3000
 3005
 3010
 3015
 3020
 3025
 3030
 3035
 3040
 3045
 3050
 3055
 3060
 3065
 3070
 3075
 3080
 3085
 3090
 3095
 3100
 3105
 3110
 3115
 3120
 3125
 3130
 3135
 3140
 3145
 3150
 3155
 3160
 3165
 3170
 3175
 3180
 3185
 3190
 3195
 3200
 3205
 3210
 3215
 3220
 3225
 3230
 3235
 3240
 3245
 3250
 3255
 3260
 3265
 3270
 3275
 3280
 3285
 3290
 3295
 3300
 3305
 3310
 3315
 3320
 3325
 3330
 3335
 3340
 3345
 3350
 3355
 3360
 3365
 3370
 3375
 3380
 3385
 3390
 3395
 3400
 3405
 3410
 3415
 3420
 3425
 3430
 3435
 3440
 3445
 3450
 3455
 3460
 3465
 3470
 3475
 3480
 3485
 3490
 3495
 3500
 3505
 3510
 3515
 3520
 3525
 3530
 3535
 3540
 3545
 3550
 3555
 3560
 3565
 3570
 3575
 3580
 3585
 3590
 3595
 3600
 3605
 3610
 3615
 3620
 3625
 3630
 3635
 3640
 3645
 3650
 3655
 3660
 3665
 3670
 3675
 3680
 3685
 3690
 3695
 3700
 3705
 3710
 3715
 3720
 3725
 3730
 3735
 3740
 3745
 3750
 3755
 3760
 3765
 3770
 3775
 3780
 3785
 3790
 3795
 3800
 3805
 3810
 3815
 3820
 3825
 3830
 3835
 3840
 3845
 3850
 3855
 3860
 3865
 3870
 3875
 3880
 3885
 3890
 3895
 3900
 3905
 3910
 3915
 3920
 3925
 3930
 3935
 3940
 3945
 3950
 3955
 3960
 3965
 3970
 3975
 3980
 3985
 3990
 3995
 4000
 4005
 4010
 4015
 4020
 4025
 4030
 4035
 4040
 4045
 4050
 4055
 4060
 4065
 4070
 4075
 4080
 4085
 4090
 4095
 4100
 4105
 4110
 4115
 4120
 4125
 4130
 4135
 4140
 4145
 4150
 4155
 4160
 4165
 4170
 4175
 4180
 4185
 4190
 4195
 4200
 4205
 4210
 4215
 4220
 4225
 4230
 4235
 4240
 4245
 4250
 4255
 4260
 4265
 4270
 4275
 4280
 4285
 4290
 4295
 4300
 4305
 4310
 4315
 4320
 4325
 4330
 4335
 4340
 4345
 4350
 4355
 4360
 4365
 4370
 4375
 4380
 4385
 4390
 4395
 4400
 4405
 4410
 4415
 4420
 4425
 4430
 4435
 4440
 4445
 4450
 4455
 4460
 4465
 4470
 4475
 4480
 4485
 4490
 4495
 4500
 4505
 4510
 4515
 4520
 4525
 4530
 4535
 4540
 4545
 4550
 4555
 4560
 4565
 4570
 4575
 4580
 4585
 4590
 4595
 4600
 4605
 4610
 4615
 4620
 4625
 4630
 4635
 4640
 4645
 4650
 4655
 4660
 4665
 4670
 4675
 4680
 4685
 4690
 4695
 4700
 4705
 4710
 4715
 4720
 4725
 4730
 4735
 4740
 4745
 4750
 4755
 4760
 4765
 4770
 4775
 4780
 4785
 4790
 4795
 4800
 4805
 4810
 4815
 4820
 4825
 4830
 4835
 4840
 4845
 4850
 4855
 4860
 4865
 4870
 4875
 4880
 4885
 4890
 4895
 4900
 4905
 4910
 4915
 4920
 4925
 4930
 4935
 4940
 4945
 4950
 4955
 4960
 4965
 4970
 4975
 4980
 4985
 4990
 4995
 5000
 5005
 5010
 5015
 5020
 5025
 5030
 5035
 5040
 5045
 5050
 5055
 5060
 5065
 5070
 5075
 5080
 5085
 5090
 5095
 5100
 5105
 5110
 5115
 5120
 5125
 5130
 5135
 5140
 5145
 5150
 5155
 5160
 5165
 5170
 5175
 5180
 5185
 5190
 5195
 5200
 5205
 5210
 5215
 5220
 5225
 5230
 5235
 5240
 5245
 5250
 5255
 5260
 5265
 5270
 5275
 5280
 5285
 5290
 5295
 5300
 5305
 5310
 5315
 5320
 5325
 5330
 5335
 5340
 5345
 5350
 5355
 5360
 5365
 5370
 5375
 5380
 5385
 5390
 5395
 5400
 5405
 5410
 5415
 5420
 5425
 5430
 5435
 5440
 5445
 5450
 5455
 5460
 5465
 5470
 5475
 5480
 5485
 5490
 5495
 5500
 5505
 5510
 5515
 5520
 5525
 5530
 5535
 5540
 5545
 5550
 5555
 5560
 5565
 5570
 5575
 5580
 5585
 5590
 5595
 5600
 5605
 5610
 5615
 5620
 5625
 5630
 5635
 5640
 5645
 5650
 5655
 5660
 5665
 5670
 5675
 5680
 5685
 5690
 5695
 5700
 5705
 5710
 5715
 5720
 5725
 5730
 5735
 5740
 5745
 5750
 5755
 5760
 5765
 5770
 5775
 5780
 5785
 5790
 5795
 5800
 5805
 5810
 5815
 5820
 5825
 5830
 5835
 5840
 5845
 5850
 5855
 5860
 5865
 5870
 5875
 5880
 5885
 5890
 5895
 5900
 5905
 5910
 5915
 5920
 5925
 5930
 5935
 5940
 5945
 5950
 5955
 5960
 5965
 5970
 5975
 5980
 5985
 5990
 5995
 6000
 6005
 6010
 6015
 6020
 6025
 6030
 6035
 6040
 6045
 6050
 6055
 6060
 6065
 6070
 6075
 6080
 6085
 6090
 6095
 6100
 6105
 6110
 6115
 6120
 6125
 6130
 6135
 6140
 6145
 6150
 6155
 6160
 6165
 6170
 6175
 6180
 6185
 6190
 6195
 6200
 6205
 6210
 6215
 6220
 6225
 6230
 6235
 6240
 6245
 6250
 6255
 6260
 6265
 6270
 6275
 6280
 6285
 6290
 6295
 6300
 6305
 6310
 6315
 6320
 6325
 6330
 6335
 6340
 6345
 6350
 6355
 6360
 6365
 6370
 6375
 6380
 6385
 6390
 6395
 6400
 6405
 6410
 6415
 6420
 6425
 6430
 6435
 6440
 6445
 6450
 6455
 6460
 6465
 6470
 6475
 6480
 6485
 6490
 6495
 6500
 6505
 6510
 6515
 6520
 6525
 6530
 6535
 6540
 6545
 6550
 6555
 6560
 6565
 6570
 6575
 6580
 6585
 6590
 6595
 6600
 6605
 6610
 6615
 6620
 6625
 6630
 6635
 6640
 6645
 6650
 6655
 6660
 6665
 6670
 6675
 6680
 6685
 6690
 6695
 6700
 6705
 6710
 6715
 6720
 6725
 6730
 6735
 6740
 6745
 6750
 6755
 6760
 6765
 6770
 6775
 6780
 6785
 6790
 6795
 6800
 6805
 6810
 6815
 6820
 6825
 6830
 6835
 6840
 6845
 6850
 6855
 6860
 6865
 6870
 6875
 6880
 6885
 6890
 6895
 6900
 6905
 6910
 6915
 6920
 6925
 6930
 6935
 6940
 6945
 6950
 6955
 6960

EP 0 723 013 A2

20. A host cell for use in the process of any one of claims 1 to 9 which contains the synthetic nucleic acid molecule of claim 19.

21. The host cell of claim 20 which is a prokaryotic or eukaryotic host cell, for example E. coli, bacillus, yeasts or animal cells (e.g. CHO or myeloma).

10

15

20

25

30

35

40

45

50

55

FIG. 1-1

COP1 COP5 COP7 COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP3										a) b)		a) b)		beta :		1 2 3:		Inhib::	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP5										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP7										: : VG1 DPP OP1 CBMP2 : CBMP3 beta-		a) b):(bov)Inhibin		beta-		TGF- : MIS alpha::		consensus	
COP4																			

Y,f,n	:	H	N	:	N	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
Y,f,n	:	Y	N	:	C	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
c	:	C	N	:	A	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
e,h,*	:	H	N	:	S	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
g	:	G	N	:	G	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
e,a*	:	G	N	:	P	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
c	:	C	N	:	C	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
p,a,g,q	:	G	N	:	P	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
f,y	:	L	N	:	Y	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
p	:	H	N	:	I	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
l,m,i	:	I	N	:	P	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
p,a,s,t	:	P	N	:	S	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
d,e,s,g*	:	P	N	:	D	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
h,r,n,s*	:	N	N	:	R	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
m,l,f,p,sa	:	L	N	:	L	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
n,k	:	S	N	:	N	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
s,a,p,g	:	L	N	:	P	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
t,s,a	:	P	N	:	R	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
n	:	V	N	:	Y	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
	:	P	N	:	G	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T	L	V	N
	:	G	N	:	N	N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	:	A	I	V	Q	T</			

[illegible]

[illegible]




FIG. 2A

FIG. 2 B-1

COP-5 fusion protein

```

      10      20      30      40      50
ATGAAAGCAATTTTCGTA CTGAAAGGTTCACTGGACAGAGATCTGGACTC
M K A I F V L K G S L D R D L D S
                               BglII

      60      70      80      90     100
TCGTCTGGATCTGGACGTTTCGTACCGACCACAAAGACCTGTCTGATCACC
R L D L D V R T D H K D L S D H

      110     120     130     140     150
TGTTCTGGTCGACCTGGCTCGTAACGACCTGGCTCGTATCGTTACTCCC
L V L V D L A R N D L A R I V T P
      SalI                               Sma

      160     170     180     190     200
GGGTCTCGTTACGTTGCGGATCTGGAATTCATGGCTGACAACAAATTCAA
G S R Y V A D L E F M A D N K F N
I                               EcoRI

      210     220     230     240     250
CAAGGAACAGCAGAACGCGTTCTACGAGATCTTGACCTGCCGAACCTGA
K E Q Q N A F Y E I L H L P N L
              MluI           BglII       BspMI+

      260     270     280     290     300
ACGAAGAGCAGCGTAACGGCTTCATCCAAAGCTTGAAGGATGAGCCCTCT
N E E Q R N G F I Q S L K D E P S
                               HindIII

      310     320     330     340     350
CAGTCTGCCAATCTGCTAGCGGATGCCAAGAACTGAACGATGCGCAGGC
Q S A N L L A D A K K L N D A Q A
              NheI                               FspI

      360     370     380     390     400
ACCGAAATCGGATCAGGGGCAATTCATGGCTGACAACAAATTCAACAAGG
P K S D Q G Q F M A D N K F N K

      410     420     430     440     450
AACAGCAGAACGCGTTCTACGAGATCTTGACCTGCCGAACCTGAACGAA
E Q Q N A F Y E I L H L P N L N E
      MluI           BglII       BspMI+

      460     470     480     490     500
GAGCAGCGTAACGGCTTCATCCAAAGCTTGAAGGATGAGCCCTCTCAGTC
E Q R N G F I Q S L K D E P S Q S
                               HindIII

```

FIG. 2B-2

```

      510      520      530      540      550
TGC GAATCTGCTAGCGGATGCCAAGAACTGAACGATGCGCAGGCACCGA
  A  N  L  L  A  D  A  K  K  L  N  D  A  Q  A  P
      NheI                      FspI

      560      570      580      590      600
AGGATCCTAATGGGCTGTACGTCGACTTCAGCGACGTGGGCTGGGACGAC
  K  D  P  N  G  L  Y  V  D  F  S  D  V  G  W  D  D
      BamHI                      SalI

      610      620      630      640      650
TGGATTGTGGCCCCACCAGGCTACCAGGCCTTCTACTGCCATGGCGAATG
  W  I  V  A  P  P  G  Y  Q  A  F  Y  C  H  G  E  C
                        StuI          NcoI  BsmI+

      660      670      680      690      700
CCCTTTCCCGCTAGCGGATCACTTCAACAGCACCAACCACGCCGTGGTGC
  P  F  P  L  A  D  H  F  N  S  T  N  H  A  V  V
      NheI                      DraIII
                                PflMI

      710      720      730      740      750
AGACCCTGGTGAAGTCTGTCAACTCCAAGATCCCTAAGGCTTGCTGCGTG
  Q  T  L  V  N  S  V  N  S  K  I  P  K  A  C  C  V
                        MstII

      760      770      780      790      800
CCCACCGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATGAGAA
  P  T  E  L  S  A  I  S  M  L  Y  L  D  E  N  E  K
                        SphI

      810      820      830      840      850
GGTGGTGCTGAAGAACTACCAGGAGATGGTAGTAGAGGGCTGCCGGCTGCC
  V  V  L  K  N  Y  Q  E  M  V  V  E  G  C  G  C
                        PflMI

      860
GCTAACTGCAG
R  *
      PstI

```

FIG. 3A




FIG. 3B



FIG. 4

10 20 30 40 50
GATCCTAATGGGCTGTACGTGGACTTCCAGCGCGACGTGGGCTGGGACGA
D P N G L Y V D F Q R D V G W D D

60 70 80 90 100
CTGGATCATCGCCCCGTCGACTTCGACGCCTACTACTGCTCCGGAGCCT
W I I A P V D F D A Y Y C S G A

110 120 130 140 150
GCCAGTTCCCCTCTGCGGATCACTTCAACAGCACCAACCACGCCGTGGTG
C Q F P S A D H F N S T N H A V V

160 170 180 190 200
CAGACCCTGGTGAACAACATGAACCCCGGCAAGGTACCCAAGCCCTGCTG
Q T L V N N M N P G K V P K P C C

210 220 230 240 250
CGTGCCACCGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATT
V P T E L S A I S M L Y L D E N

260 270 280 290 300
CCACCGTGGTGCTGAAGAACTACCAGGAGATGACCGTGGTGGGCTGCGGC
S T V V L K N Y Q E M T V V G C G

310
TGCCGCTAACTGCAG
C R *

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 723 013 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
14.01.1998 Bulletin 1998/03

(43) Date of publication A2:
24.07.1996 Bulletin 1996/30

(21) Application number: **96200044.4**

(22) Date of filing: **07.04.1989**

(51) Int. Cl.⁶: **C12N 15/12**, C07K 14/51,
C07K 16/22, A61K 38/18,
A61L 27/00, C12N 1/21

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: **08.04.1988 US 179406**
15.08.1988 US 232630
23.02.1989 US 315342

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
89904959.7 / 0 372 031

(71) Applicant: **STRYKER CORPORATION**
Kalamazoo, Michigan 49003-4085 (US)

(72) Inventors:

- **Opperman, Hermann**
Medway, Massachusetts 02053 (US)
- **Kuberasampath, Thangavel**
Medway, Massachusetts 02053 (US)
- **Rueger, David C.**
West Roxbury, Massachusetts 02132 (US)

(74) Representative:

Price, Vincent Andrew et al
FRY HEATH & SPENCE
The Old College
53 High Street
Horley Surrey RH6 7BN (GB)

(54) **Biosynthetic osteogenic proteins and osteogenic devices containing them**

(57) Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth and cartilage in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.

EP 0 723 013 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 20 0044

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.4)
X	EP 0 169 016 A (COLAGEN CORPORATION) 22 January 1986	1	C12N15/12 C07K14/51 C07K16/22 A61K38/18 A61L27/00 C12N1/21
A	* Claim 1; page 1, lines 5-11; page 5, lines 7-35 *	2-23	
A	--- WO 88 00205 A (GENETICS INSTITUTE, INC.) 14 January 1988 * claims 11-14 *	1-23	
A	--- PADGETT, R.W. ET AL.: "A transcript from drosophila pattern gene predicts a protein homologous to the transforming growth factor-beta family" NATURE, vol. 325, 1987, page 81-84 XP002036812 * figures 3 and 4 *	1-23	
T	--- ÖZKAYNAK, E. ET AL.: "OP-1 cDNA encodes an osteogenic protein in the TGF-beta family" EMBO J., vol. 9, no. 7, 1990, page 2085-2093 XP000611252 * abstract *	1-23	
E	--- WO 90 11366 A (GENETICS INSTITUTE, INC) 4 October 1990 * claims; tabs II, IV, V *	1,2,9-23	TECHNICAL FIELDS SEARCHED (Int.Cl.4)
T	--- CELESTE, A.J ET AL.: "Identification of transforming growth factor beta family members ..." PROC. NATL. ACAD. SCI. USA, vol. 87, no. 24, 1990, pages 9843-9847, XP000168624 * whole disclosure *	1-23	C07K C12N A61K A61L
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 7 November 1997	Examiner Hermann, R
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 82 (P04C01)



European Patent Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

See sheet -B-

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



European Patent Office

- B -

LACK OF UNITY OF INVENTION**ANNEX TO SHEET B**

NB: After receipt of the first Partial European Search Report, applicants have complied with the demand of the searching authority to better define the remaining subject(s) to be searched.

The subject matter already searched, and the remaining invention to be searched has now been properly defined in the form of an amended set of claims (R. 86(2) EPC).

The searched inventions as defined below correspond to said amended set of claims.

1st invention:

Claims 3-9; 10,11 partially (corresponding to original claims 1-9): A process for producing active synthetic osteogenic protein.

2nd invention:

Claims 1-2, 12-23; 10,11 partially: Osteogenic protein comprising six cysteine residues in defined positions; compositions comprising it; antibodies reactive with said protein; devices comprising said protein; uses of said protein; synthetic nucleic acids coding for said protein or proteins resulting from the process of invention 1; host cells containing said nucleic acids.